1
|
Batra J, Mourad M, Collado FK, Takeda K, Greenwald A, Ring L, Chen X, Haythe J. Case report of pregnancy complicated by severe pulmonary hypertension from mitral stenosis and placenta accreta spectrum disorder: management of two life-threatening conditions. Eur Heart J Case Rep 2024; 8:ytae055. [PMID: 38425728 PMCID: PMC10903160 DOI: 10.1093/ehjcr/ytae055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2023] [Revised: 01/20/2024] [Accepted: 01/24/2024] [Indexed: 03/02/2024]
Abstract
Background Antenatal cardiovascular disease is a major cause of maternal morbidity and mortality. Severe rheumatic mitral stenosis is especially poorly tolerated during pregnancy. Case Summary We present a young woman with severe pulmonary hypertension secondary to rheumatic mitral stenosis. She presented at 25 weeks 4 days gestation for evaluation of a pregnancy complicated by placenta accreta spectrum disorder. Invasive hemodynamic testing was carried out to delineate her hemodynamics, and a multidisciplinary cardio-obstetrics team collaborated closely with the patient and her partner to create a management plan. Ultimately, the patient was initiated on veno-arterial extracorporeal membrane oxygenation and underwent caesarean section delivery followed by hysterectomy and subsequent valve replacement surgery. Discussion This case describes the treatment options considered to balance the risk of decompensation in the setting of severe pulmonary hypertension with hemorrhage associated with placenta accreta spectrum disorder. It highlights the importance of a multidisciplinary, team-based approach to the management of high-risk cardiac conditions throughout pregnancy.
Collapse
Affiliation(s)
- Jaya Batra
- Division of Cardiology, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, 630 W 168th St, PH 12 STEM, New York, NY 10032, USA
| | - Mirella Mourad
- Department of Obstetrics and Gynecology, Columbia University Vagelos College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032, USA
| | - Fady Khoury Collado
- Department of Obstetrics and Gynecology, Columbia University Vagelos College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032, USA
| | - Koji Takeda
- Division of Cardiac, Thoracic, and Vascular Surgery, Department of Surgery, Columbia University Vagelos College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032, USA
| | - Andrew Greenwald
- Department of Anesthesiology, Columbia University Vagelos College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032, USA
| | - Laurence Ring
- Department of Anesthesiology, Columbia University Vagelos College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032, USA
| | - Xuxin Chen
- Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032, USA
| | - Jennifer Haythe
- Division of Cardiology, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, 630 W 168th St, PH 12 STEM, New York, NY 10032, USA
| |
Collapse
|
2
|
Batra J, DeFilippis EM, Clerkin K, Bae D, Oh KT, Lotan D, Topkara VK, Lee SH, Latif F, Colombo P, Yuzefpolskaya M, Raikhelkar J, Majure DT, Sayer G, Uriel N. A change of heart: Characteristics and outcomes of multiple cardiac retransplant recipients. Clin Transplant 2024; 38:e15214. [PMID: 38078705 DOI: 10.1111/ctr.15214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Revised: 11/07/2023] [Accepted: 11/17/2023] [Indexed: 01/31/2024]
Abstract
BACKGROUND Among heart transplant (HT) recipients who develop advanced graft dysfunction, cardiac re-transplantation may be considered. A smaller subset of patients will experience failure of their second allograft and undergo repeat re-transplantation. Outcomes among these individuals are not well-described. METHODS Adult and pediatric patients in the United Network for Organ Sharing (UNOS) registry who received HT between January 1, 1990 and December 31, 2020 were included. RESULTS Between 1990 and 2020, 90 individuals received a third HT and three underwent a fourth HT. Recipients were younger than those undergoing primary HT (mean age 32 years). Third HT was associated with significantly higher unadjusted rates of 1-year mortality (18% for third HT vs. 13% for second HT vs. 9% for primary HT, p < .001) and 10-year mortality (59% for third HT vs. 42% for second HT vs. 37% for primary HT, p < .001). Mortality was highest amongst recipients aged >60 years and those re-transplanted for acute graft failure. Long-term rates of CAV, rejection, chronic dialysis, and hospitalization for infection were also higher. CONCLUSIONS Third HT is associated with higher morbidity and mortality than primary HT. Further consensus is needed regarding appropriate organ stewardship for this unique subgroup.
Collapse
Affiliation(s)
- Jaya Batra
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Ersilia M DeFilippis
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Kevin Clerkin
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - David Bae
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Kyung Taek Oh
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Dor Lotan
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Veli K Topkara
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Sun Hi Lee
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Farhana Latif
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Paolo Colombo
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Melana Yuzefpolskaya
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Jayant Raikhelkar
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - David T Majure
- Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York, New York, USA
| | - Gabriel Sayer
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Nir Uriel
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| |
Collapse
|
3
|
Batra J, Haythe J, Purisch S. A Case of a Cardiac Hamartoma in Pregnancy: Preconception Through Delivery. JACC Case Rep 2023; 28:102128. [PMID: 38204524 PMCID: PMC10774817 DOI: 10.1016/j.jaccas.2023.102128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2023] [Revised: 10/25/2023] [Accepted: 10/31/2023] [Indexed: 01/12/2024]
Abstract
A 32-year-old woman with a large cardiac hamartoma was referred to our institution's cardio-obstetrics group for preconception counseling. Results of hemodynamic testing revealed restrictive physiology. This case highlights the role of multimodality testing in predicting the hemodynamic consequences of pregnancy in the setting of high-risk cardiovascular conditions.
Collapse
Affiliation(s)
- Jaya Batra
- Division of Cardiology, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA
| | - Jennifer Haythe
- Division of Cardiology, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA
| | - Stephanie Purisch
- Department of Obstetrics and Gynecology, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA
| |
Collapse
|
4
|
Batra A, Batra J, Pathare T. Case Report: Rare Presentation of Nodular Fasciitis over Dorsum of Wrist. J Orthop Case Rep 2023; 13:157-161. [PMID: 38025358 PMCID: PMC10664211 DOI: 10.13107/jocr.2023.v13.i11.4044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2023] [Revised: 09/05/2023] [Indexed: 12/01/2023] Open
Abstract
Introduction Nodular fasciitis is a benign, reactive fibroblastic tumor that usually presents as a rapidly growing lesion with occasional involvement of the deep fascia and muscle. We present a case of nodular fasciitis over the dorsum of the wrist. In our knowledge, this is the first reported case of nodular fasciitis at this location in the literature. Case Report A 33-year-old South Asian male with a desk job, presented with a rapidly growing lesion over the dorsum of the left wrist over 5 months, associated with pain and restriction of dorsiflexion of wrist. The X-ray, ultrasound, and magnetic resonance imaging images were inconclusive and excisional biopsy was done for definitive diagnosis. Conclusion Nodular fasciitis is a relatively uncommon but important differential diagnosis for any rapid soft-tissue growth. It is a self-limiting proliferative fibroblastic lesion, with excisional biopsy as the gold standard for diagnosis of this condition.
Collapse
Affiliation(s)
- Ashootosh Batra
- Department of Orthopedic Surgery, Medeor Hospital, Abu Dhabi, UAE
| | - Jaya Batra
- Department of Anesthesia and Pain Management, Cleveland Clinic, Abu Dhabi, UAE
| | - Tripti Pathare
- Department of Radiology, Medeor Hospital, Abu Dhabi, UAE
| |
Collapse
|
5
|
Defilippis EM, Batra J, Blumer V, Peoples IA, Taylor CN, Oren D, Lopez J, Sauer AJ, Ibrahim NE. Organ Donation and Transplantation among Non-US Citizens: Opportunities to Improve Global Equity in Heart Transplantation. J Card Fail 2023; 29:1383-1393. [PMID: 37088281 DOI: 10.1016/j.cardfail.2023.04.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2023] [Revised: 03/31/2023] [Accepted: 04/06/2023] [Indexed: 04/25/2023]
Abstract
BACKGROUND Non-US citizens/non-US residents (NCNR) are a unique and growing population. Patterns of heart donation and heart transplantation (HT) within this subgroup have not been described fully. The purpose of this study was to evaluate the use of organs from NCNR donors and the characteristics and outcomes of NCNR HT recipients. METHODS All adult donors whose hearts were recovered for HT and all primary adult HT recipients from 2013 to 2020 were identified using the United Network for Organ Sharing. Donors and recipients were categorized as citizens, residents, or NCNR. NCNR were further categorized by reason for travel to the United States. Outcomes included mortality, infection, and rejection at 1-year after transplantation. RESULTS NCNR accounted for 0.4% (n = 77) of heart donors. Most NCNR donors identified as Hispanic (61%), were predominately recovered from the South and Southwest United States, and were less likely to express written documentation to be a donor compared with citizens and residents. NCNR accounted for 0.7% (n = 147) of all HT recipients. The majority identified as non-Hispanic White individuals (57.1%). Compared with citizens and residents, NCNR recipients seemed to be sicker, as evidenced by higher intra-aortic balloon pump use before HT and higher priority United Network for Organ Sharing status. Of NCNR recipients, 63% traveled to the United States for HT, predominately from Kuwait (29.9%) and Saudi Arabia (20%). At 1-year after transplant, there were no differences in mortality, infection, or rejection between the groups. CONCLUSIONS A growing subgroup of NCNR travel from countries with low HT rates to the United States for HT. This finding highlights the need for strategies to improve equitable access to HT domestically and abroad.
Collapse
Affiliation(s)
- Ersilia M Defilippis
- Division of Cardiology, Columbia University Irving Medical Center, New York, New York
| | - Jaya Batra
- Division of Cardiology, Columbia University Irving Medical Center, New York, New York
| | | | | | | | - Daniel Oren
- New York Presbyterian - Brooklyn Methodist Hospital, Brooklyn, New York
| | - Jose Lopez
- Department of Internal Medicine, HCA Florida Aventura Hospital, Aventura, Florida
| | - Andrew J Sauer
- Saint Luke's Mid America Heart Institute, Kansas City, Missouri
| | | |
Collapse
|
6
|
DeFilippis EM, Batra J, Donald E, Rubin G, Jou S, Razzaq A, Wan EY, Garan H, Takeda K, Sayer G, Uriel N, Topkara VK, Biviano A, Yarmohammadi H. Long-Term Outcomes of Permanent Pacemaker Implantation in Bicaval Heart Transplant Recipients. JACC Clin Electrophysiol 2023; 9:1964-1971. [PMID: 37480861 DOI: 10.1016/j.jacep.2023.05.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2022] [Revised: 05/08/2023] [Accepted: 05/15/2023] [Indexed: 07/24/2023]
Abstract
BACKGROUND Permanent pacemakers (PPMs) may be necessary in up to 10% of patients after heart transplantation (HT). OBJECTIVES The purpose of this study was to evaluate long-term outcomes and clinical courses of heart transplant recipients who received PPM. METHODS All patients who required PPM after bicaval HT at Columbia University between January 2005 and December 2021 were included. Cases were compared to matched heart transplant recipients by age, sex, and year of transplantation. Patient and device characteristics including complications and device interrogations were reviewed. Outcomes of re-transplantation or graft failure/death were compared between groups. RESULTS Of 1,082 heart transplant recipients, 41 (3.8%) received PPMs. The median time from transplantation to PPM was 118 days (IQR: 18-920 days). The most common indications were sinus node dysfunction (60%, n = 25) and atrioventricular (AV) nodal disease (41.5%, n = 17). Post-implantation complications included pocket hematoma (n = 3), lead under-sensing (n = 2), and pocket infection requiring explant (n = 1). Rates of death and re-transplantation at 10 years post-HT were similar between groups. In multivariable analysis, after adjustment for mechanical circulatory support, pretransplantation amiodarone use, donor ischemic time and age, only older donor age was associated with increased risk of PPM implantation (P = 0.03). There was a significant decrease in PPM placement after 2018 (1.2% vs 4.4%, P = 0.02), largely driven by a decline in early PPM placement. There were no differences in mortality or need for re-transplantation between groups. CONCLUSIONS PPMs are implanted after HT for sinus and atrioventricular node dysfunctions with low incidence of device-related complications. Our study shows a decrease in PPM implantation after 2018, likely attributable to expectant management in the early postoperative period.
Collapse
Affiliation(s)
- Ersilia M DeFilippis
- Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA
| | - Jaya Batra
- Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA
| | - Elena Donald
- Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA
| | - Geoffrey Rubin
- Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA
| | - Stephanie Jou
- Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA
| | - Ansa Razzaq
- Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA
| | - Elaine Y Wan
- Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA
| | - Hasan Garan
- Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA
| | - Koji Takeda
- Division of Cardiothoracic Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, New York, USA
| | - Gabriel Sayer
- Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA
| | - Nir Uriel
- Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA
| | - Veli K Topkara
- Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA
| | - Angelo Biviano
- Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA
| | - Hirad Yarmohammadi
- Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
| |
Collapse
|
7
|
Batra J, Topkara V, Clerkin K, Latif F, Fried J, Raikhelkar J, Lotan D, Donald E, Lumish H, Oh K, Yuzefpolskaya M, Colombo P, Lin E, Sayer G, Uriel N. Multi-Organ Transplantation in Hiv-Positive Recipients - Patient Characteristics and Outcomes. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
8
|
Concha D, Chung A, Lumish H, Batra J, Sayer G, Clerkin K, Raikhelkar J, Colombo P, Naka Y, Latif F, Takeda K, Fried J, Yuzefpolskaya M, Kaku Y, Uriel N. Actual-to-Expected Advanced Heart Failure Therapy Utilization in the United States by Race/Ethnicity. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
9
|
Lotan D, Moeller C, Rubinstein G, Rosenblum H, DeFilippis E, Clerkin K, Raikhelkar J, Batra J, Oh K, Lin E, Fried J, Latif F, Kennel P, McLeod J, Colombo P, Lee S, Topkara V, Yuzefpolskaya M, Sayer G, Uriel N. Against All Odds - Transplanting Against 100% Reactive Antibodies and the Role of Non-Invasive Monitoring. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.1228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
10
|
Slomovich S, Rubinstein G, Moeller C, Lotan D, Mehlman Y, Donald E, Batra J, Oren D, Oh K, Clerkin K, Fried J, DeFilippis E, Topkara V, Kleet A, Colombo P, Yuzefpolskaya M, Lin E, Lee S, Majure D, Latif F, Sayer G, Uriel N, Raikhelkar J. Donor-Derived Cell-Free DNA in Cancer Survivors Following Heart Transplantation. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
11
|
Batra J, Rosenblum H, DeFilippis E, Donald E, Clerkin K, Topkara V, Lee S, Latif F, Yuzefpolskaya M, Colombo P, Oh K, Lotan D, Raikhelkar J, Sayer G, Uriel N. Characteristics and Outcomes of Multiple Cardiac Re-Transplant Recipients. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
12
|
Batra J, DeFilippis EM, Golob S, Lumish H, Clerkin K, Topkara VK, Restaino S, Lee SH, Latif F, Raikhelkar J, Fried J, Oh KT, Lin E, Colombo PC, Yuzefpolskaya M, Sayer G, Uriel N. Early post-transplant leukopenia in heart transplant recipients and its impact on outcomes. Clin Transplant 2023; 37:e14934. [PMID: 36798992 DOI: 10.1111/ctr.14934] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2022] [Revised: 01/11/2023] [Accepted: 02/08/2023] [Indexed: 02/18/2023]
Abstract
BACKGROUND Leukopenia in the early period following heart transplantation (HT) is not well-studied. The aim of this study was to evaluate risk factors for the development of post-transplant leukopenia and its consequences for HT recipients. METHODS Adult patients at a large-volume transplant center who received HT between January 1, 2010 and December 31, 2020 were included. The incidence of leukopenia (WBC ≤3 × 103 /μL) in the first 90-days following HT, individual risk factors, and its effect on 1-year outcomes were evaluated. RESULTS Of 506 HT recipients, 184 (36%) developed leukopenia within 90-days. Median duration of the first leukopenia episode was 15.5 days (IQR 8-42.5 days). Individuals who developed leukopenia had lower pre-transplant WBC counts compared to those who did not (6.1 × 103 /μL vs. 6.9 × 103 /μL, p = .02). Initial immunosuppressive and infectious chemoprophylactic regimens were not significantly different between groups. Early leukopenia was associated with a higher mortality at 1-year (6.6% vs. 2.1%, p = .008; adjusted HR 3.0) and an increased risk of recurrent episodes. Rates of infection and rejection were not significantly different between the two groups. CONCLUSIONS Leukopenia in the early period following HT is common and associated with an increased risk of mortality. Further study is needed to identify individuals at highest risk for leukopenia prior to transplant and optimize immunosuppressive and infectious chemoprophylactic regimens for this subgroup.
Collapse
Affiliation(s)
- Jaya Batra
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Ersilia M DeFilippis
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Stephanie Golob
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Heidi Lumish
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Kevin Clerkin
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Veli K Topkara
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Susan Restaino
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Sun Hi Lee
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Farhana Latif
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Jayant Raikhelkar
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Justin Fried
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Kyung Taek Oh
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Edward Lin
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Paolo C Colombo
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Melana Yuzefpolskaya
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Gabriel Sayer
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Nir Uriel
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| |
Collapse
|
13
|
Golob S, Batra J, DeFilippis EM, Uriel M, Carey M, Gaine M, Mabasa A, Fried J, Raikelkar J, Restaino S, Hi Lee S, Latif F, Yuzefpolskaya M, Colombo PC, Choe J, Majure D, Jennings D, Pereira MR, Clerkin K, Sayer G, Uriel N. Letermovir for cytomegalovirus prophylaxis in high-risk heart transplant recipients. Clin Transplant 2022; 36:e14808. [PMID: 36086937 DOI: 10.1111/ctr.14808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2022] [Revised: 06/28/2022] [Accepted: 08/10/2022] [Indexed: 12/27/2022]
Abstract
Letermovir is a novel agent for the prevention of cytomegalovirus (CMV) infection and disease that, unlike traditional CMV DNA polymerase inhibitors, does not carry the risk of myelosuppression. The purpose of this study was to evaluate the safety, efficacy, and clinical application of letermovir for CMV prophylaxis in heart transplant (HT) recipients. Between November 1, 2019, and October 1, 2021, at a single, tertiary care hospital, 17 HT recipients were initiated on letermovir due to leukopenia while on valganciclovir. Fifteen (88%) had high-risk mismatch (CMV D+/R-). Median time on letermovir was 5 months (interquartile range, 2-8 months.) At the end of the study period, nine of 17 patients (52.9%) were still on letermovir and four of the 17 (23.5%) had successfully completed the prophylaxis window on letermovir and been switched to the pre-emptive strategy. One patient developed clinically significant CMV viremia in the setting of being unable to obtain medication due to insurance barriers but was later successfully restarted on letermovir. One patient was unable to tolerate letermovir due to symptoms of headache and myalgias. Two patients developed low-level non-clinically significant CMV viremia and were switched back to valacyclovir. All patients had tacrolimus dosages reduced at time of letermovir initiation to minimize the risk of supratherapeutic tacrolimus concentration. One patient required hospitalization due to symptomatic tacrolimus toxicity. For HT recipients who cannot tolerate valganciclovir, letermovir presents an alternative for CMV prophylaxis. Close monitoring for breakthrough CMV and calcineurin inhibitor levels is necessary. Larger studies are required to further delineate its use and help provide further evidence of its safety and efficacy.
Collapse
Affiliation(s)
- Stephanie Golob
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Jaya Batra
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Ersilia M DeFilippis
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Matan Uriel
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Matt Carey
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Maureen Gaine
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Angelo Mabasa
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Justin Fried
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Jayant Raikelkar
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Susan Restaino
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Sun Hi Lee
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Farhana Latif
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Melana Yuzefpolskaya
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Paolo C Colombo
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Jason Choe
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - David Majure
- Division of Cardiology, Department of Medicine, Cornell University, Ithaca, New York, USA
| | - Douglas Jennings
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Marcus R Pereira
- Division of Infectious Disease, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Kevin Clerkin
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Gabriel Sayer
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Nir Uriel
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| |
Collapse
|
14
|
Wu X, Liyanage C, Plan M, Stark T, McCubbin T, Barrero RA, Batra J, Crawford R, Xiao Y, Prasadam I. Dysregulated energy metabolism impairs chondrocyte function in osteoarthritis. Osteoarthritis Cartilage 2022; 31:613-626. [PMID: 36410637 DOI: 10.1016/j.joca.2022.11.004] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/27/2022] [Revised: 11/07/2022] [Accepted: 11/12/2022] [Indexed: 11/21/2022]
Abstract
OBJECTIVES Metabolic pathways are a series of chemical reactions by which cells take in nutrient substrates for energy and building blocks needed to maintain critical cellular processes. Details of chondrocyte metabolism and how it rewires during the progression of osteoarthritis (OA) are unknown. This research aims to identify what changes in the energy metabolic state occur in OA cartilage. METHODS Patient matched OA and non-OA cartilage specimens were harvested from total knee replacement patients. Cartilage was first collected for metabolomics, proteomics, and transcriptomics analyses to study global alterations in OA metabolism. We then determined the metabolic routes by tracking [U-13C] isotope with liquid chromatography-mass spectrometry (LC-MS). We further evaluated cellular bioenergetic profiles by measuring oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) and investigated the effects of low-dose and short-term effects of 2-deoxyglucose (2DG) on chondrocytes. RESULTS OA chondrocytes showed increased basal ECAR and more lactate production compared to non-OA chondrocytes. [U-13C] glucose labelling revealed that less glucose-derived carbon entered the tricarboxylic acid (TCA) cycle. On the other hand, mitochondrial respiratory rates were markedly decreased in the OA chondrocytes compared to non-OA chondrocytes. These changes were accompanied by decreased cellular ATP production, mitochondrial membrane potential and disrupted mitochondrial morphology. We further demonstrated in vitro that short-term inhibition of glycolysis suppressed matrix degeneration gene expression in chondrocytes and bovine cartilage explants cultured under inflammatory conditions. CONCLUSION This study represents the first comprehensive comparative analysis of metabolism in OA chondrocytes and lays the groundwork for therapeutic targeting of metabolism in OA.
Collapse
Affiliation(s)
- X Wu
- Centre for Biomedical Technologies, Queensland University of Technology, Brisbane, QLD 4059, Australia; Department of Orthopaedic Surgery, the Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China
| | - C Liyanage
- Centre for Biomedical Technologies, Queensland University of Technology, Brisbane, QLD 4059, Australia; Australian Prostate Cancer Research Centre-Queensland, Translational Research Institute, Queensland University of Technology, Brisbane, QLD 4102, Australia
| | - M Plan
- Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia; Metabolomics Australia (Queensland Node), AIBN, The University of Queensland, Brisbane, QLD 4072, Australia
| | - T Stark
- Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia; Metabolomics Australia (Queensland Node), AIBN, The University of Queensland, Brisbane, QLD 4072, Australia
| | - T McCubbin
- Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia; Metabolomics Australia (Queensland Node), AIBN, The University of Queensland, Brisbane, QLD 4072, Australia
| | - R A Barrero
- eResearch Office, Queensland University of Technology, Brisbane, QLD 4000, Australia
| | - J Batra
- Centre for Biomedical Technologies, Queensland University of Technology, Brisbane, QLD 4059, Australia; Australian Prostate Cancer Research Centre-Queensland, Translational Research Institute, Queensland University of Technology, Brisbane, QLD 4102, Australia
| | - R Crawford
- The Prince Charles Hospital, Chermside, Brisbane, QLD 4032, Australia
| | - Y Xiao
- Centre for Biomedical Technologies, Queensland University of Technology, Brisbane, QLD 4059, Australia; Australia-China Centre for Tissue Engineering and Regenerative Medicine, Queensland University of Technology, Brisbane, QLD 4059, Australia
| | - I Prasadam
- Centre for Biomedical Technologies, Queensland University of Technology, Brisbane, QLD 4059, Australia.
| |
Collapse
|
15
|
Batra J, Rosenblum H, Cappelli F, Zampieri M, Olivotto I, Griffin JM, Saith SE, Teruya S, Santos JDL, Argiro A, Burkhoff D, Perfetto F, Maurer MS. Racial Differences in Val122Ile-Associated Transthyretin Cardiac Amyloidosis. J Card Fail 2022; 28:950-959. [PMID: 34974181 PMCID: PMC9844506 DOI: 10.1016/j.cardfail.2021.12.016] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2021] [Revised: 12/07/2021] [Accepted: 12/17/2021] [Indexed: 01/19/2023]
Abstract
BACKGROUND The valine-to-isoleucine substitution (Val122Ile) is the most common variant of transthyretin (TTR) amyloidosis in the United States, affecting primarily individuals of African descent. This variant has been identified recently in a cluster of white individuals in Italy. METHODS AND RESULTS Clinical phenotype and chamber performance of Black and white individuals with Val122Ile TTR cardiac amyloidosis (ATTR-CA) were compared. Compared to white patients (n = 17), Black individuals (n = 53) had lower systolic blood pressures (110 vs 131 mmHg, <0.001), reduced pulse pressures (41 vs 58 mmHg; P < 0.001), and impaired renal function (eGFR 46 vs 67 mL/min/1.73m2; P < 0.001) at presentation. Systolic properties and arterial elastance were similar. Black patients had end-diastolic pressure-volume relationships that were shifted upward and leftward relative to those of white patients, indicating reduced left ventricular chamber capacitance. Pressure-volume area at a left ventricular end-diastolic pressure of 30 mmHg was lower in Black than in white individuals (8055 mmHg/mL vs 11,538 mmHg/mL; P = 0.008). CONCLUSION Despite presenting at ages similar to those of white patients, Black individuals with Val122Ile-associated ATTR-CA had a greater degree of cardiac chamber dysfunction at the time of diagnosis due to impaired ventricular capacitance. Whether these differences are attributable to amyloidosis or other cardiovascular disease requires further study.
Collapse
Affiliation(s)
- Jaya Batra
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032
| | - Hannah Rosenblum
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032
| | - Francesco Cappelli
- Tuscan Regional Amyloid Center, Careggi University Hospital, Largo Brambilla 3, Florence Italy
| | - Mattia Zampieri
- Tuscan Regional Amyloid Center, Careggi University Hospital, Largo Brambilla 3, Florence Italy
| | - Iacopo Olivotto
- Cardiomyopathy Unit, Heart, Lung and Vessels Department, Careggi University Hospital, Largo Brambilla 3, Florence Italy
| | - Jan M. Griffin
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032
| | - Sunil E. Saith
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032
| | - Sergio Teruya
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032
| | - Jeffeny De Los Santos
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032
| | - Alessia Argiro
- Tuscan Regional Amyloid Center, Careggi University Hospital, Largo Brambilla 3, Florence Italy
| | - Daniel Burkhoff
- Cardiovascular Research Foundation, 1700 Broadway, New York, NY 10019
| | - Federico Perfetto
- Tuscan Regional Amyloid Center, Careggi University Hospital, Largo Brambilla 3, Florence Italy
| | - Mathew S. Maurer
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032,Corresponding author: Mathew S. Maurer, M.D., Professor of Medicine, Columbia University Medical Center, 622 W 168th street, PH 12-134, New York, NY, 10032,
| |
Collapse
|
16
|
Golob S, Uriel M, Batra J, Gaine M, Clerkin K, Raikhelkar J, Fried J, Griffin J, Restaino S, Lee S, Majure D, Yuzefpolskaya M, Colombo P, Latif F, Pereira M, Choe J, Jennings D, Sayer G, Uriel N. Use of Letermovir for Cytomegalovirus (CMV) Prophylaxis in Orthotopic Heart Transplant Recipients. J Heart Lung Transplant 2022. [DOI: 10.1016/j.healun.2022.01.1380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
17
|
Zabidi N, Chai J, Batra J, Misuan N, Yap M, Lal S. Heat Shock Proteins and Their Interplay to Control Influenza A Virus Replication. Int J Infect Dis 2022. [DOI: 10.1016/j.ijid.2021.12.219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
18
|
Yarmohammadi H, Batra J, Hennessey JA, Kochav S, Saluja D, Liu Q. Novel Use of Three-Dimensional Transthoracic Echocardiography to Guide Implantation of a Leadless Pacemaker System. HeartRhythm Case Rep 2022; 8:366-369. [PMID: 35607335 PMCID: PMC9123317 DOI: 10.1016/j.hrcr.2022.02.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Affiliation(s)
- Hirad Yarmohammadi
- Address reprint requests and correspondence: Dr Hirad Yarmohammadi, Columbia University Irving Medical Center, 177 Fort Washington Ave, Room 637, New York, NY 10032.
| | | | | | | | | | | |
Collapse
|
19
|
Batra J, DeFilippis EM, Golob S, Clerkin K, Topkara VK, Habal MV, Restaino S, Griffin J, Hi Lee S, Latif F, Farr MA, Sayer G, Raikelkar J, Uriel N. Impact of Pretransplant Malignancy on Heart Transplantation Outcomes: Contemporary United Network for Organ Sharing Analysis Amidst Evolving Cancer Therapies. Circ Heart Fail 2022; 15:e008968. [PMID: 35094567 DOI: 10.1161/circheartfailure.121.008968] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND An aging population and improved cancer survivorship have increased the number of individuals with treated malignancy who develop advanced heart failure. The benefits of heart transplantation (HT) in patients with a pretransplant malignancy (PTM) must be balanced against risks of posttransplant malignancy in the setting of immunosuppression. METHODS Adult patients in the United Network for Organ Sharing registry who received HT between January 1, 2010, and December 31, 2020 were included. Trends, patient characteristics, and posttransplant outcomes in HT recipients with PTM were evaluated. RESULTS From 2000 to 2020, the proportion of HT recipients with PTM increased from 3.2% to 8.2%. From 2010 to 2020, 2113 (7.7%) of 27 344 HT recipients had PTM. PTM was associated with higher rates of 1-year mortality after HT (11.9% versus 9.2%; adjusted hazard ratio, 1.25 [95% CI, 1.09-1.44], P=0.001), driven by increased mortality in patients with hematologic PTM (adjusted hazard ratio, 2.00 [95% CI, 1.61-2.48]; P<0.001). For recipients who survived the first year, 5-year survival was similar between patients with and without PTM. Rates of malignancy at 5-years posttransplant were higher in the PTM group (20.4% versus 13.1%; adjusted hazard ratio, 1.57 [95% CI, 1.38-1.79], P<0.001). CONCLUSIONS Prevalence of PTM in HT recipients nearly tripled over the past 2 decades. Patients with hematologic PTM were at increased risk of early mortality after HT. Patients with PTM were also at higher risk for posttransplant malignancy. Guidelines that reflect contemporary oncological care are needed to inform care of this heterogenous and expanding group of individuals.
Collapse
Affiliation(s)
- Jaya Batra
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY
| | - Ersilia M DeFilippis
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY
| | - Stephanie Golob
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY
| | - Kevin Clerkin
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY
| | - Veli K Topkara
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY
| | - Marlena V Habal
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY
| | - Susan Restaino
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY
| | - Jan Griffin
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY
| | - Sun Hi Lee
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY
| | - Farhana Latif
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY
| | - Maryjane A Farr
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY
| | - Gabriel Sayer
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY
| | - Jayant Raikelkar
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY
| | - Nir Uriel
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY
| |
Collapse
|
20
|
Batra J, Biviano A, Yarmohammadi H. Dancing Bundles With Stable Sinus Rhythm. Circulation 2022; 145:84-86. [PMID: 34965165 DOI: 10.1161/circulationaha.121.058218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Jaya Batra
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY
| | - Angelo Biviano
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY
| | - Hirad Yarmohammadi
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY
| |
Collapse
|
21
|
Argirò A, Zampieri M, Batra J, Rosenblum H, Burkhoff D, Maurer M, Olivotto I, Cappelli F. 158 Racial differences in val122Ile associated transthyretin cardiac amyloidosis. Eur Heart J Suppl 2021. [DOI: 10.1093/eurheartj/suab142.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Abstract
Aims
The valine-to-isoleucine substitution (Val122Ile) is the most common variant of transthyretin (TTR) amyloidosis in the USA, primarily affecting individuals of African descent and leading to a restrictive cardiomyopathy. This variant has recently been identified in a cluster of White individuals in Italy. In this study we aimed to investigate differences in the clinical phenotype of Val122Ile associated TTR cardiac amyloidosis (ATTR-CA) between Black and White individuals.
Methods and results
In this retrospective study of 70 patients (mean age 72 years) with Val122Ile associated TTR ATTR-CA, cardiac chamber performance was compared using noninvasive pressure-volume analysis. Compared to White patients (n = 17), Black individuals (n = 53) had lower systolic blood pressures (110 vs. 131 mmHg, P < 0.001), reduced pulse pressures (41 vs. 58 mmHg, P < 0.001), and impaired renal function (eGFR 46 vs. 67 mL/min/1.73 m2, P < 0.001) at presentation. Systolic properties and arterial elastance were similar. Black patients had an end-diastolic pressure-volume relationship shifted upward and leftward relative to White patients, indicating reduced left ventricular chamber capacitance. Pressure-volume area at a left ventricular end-diastolic pressure of 30 mmHg was lower in Black compared to White individuals (8055 mmHg*ml vs. 11 538 mmHg*ml, P = 0.008).
Conclusions
Despite presenting at a similar age to White patients, Black individuals with Val122Ile associated ATTR-CA have a greater degree of cardiac chamber dysfunction at the time of diagnosis due to impaired ventricular capacitance. Whether these differences are attributable to amyloidosis or other cardiovascular disease requires further study.
Collapse
Affiliation(s)
- Alessia Argirò
- Cardiomyopathy Unit, Heart, Lung and Vessels Department, Careggi University Hospital, Florence, Italy
| | - Mattia Zampieri
- Cardiomyopathy Unit, Heart, Lung and Vessels Department, Careggi University Hospital, Florence, Italy
| | - Jaya Batra
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, USA
| | - Hannah Rosenblum
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, USA
| | | | - Mathew Maurer
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, USA
| | - Iacopo Olivotto
- Cardiomyopathy Unit, Heart, Lung and Vessels Department, Careggi University Hospital, Florence, Italy
| | - Francesco Cappelli
- Cardiomyopathy Unit, Heart, Lung and Vessels Department, Careggi University Hospital, Florence, Italy
| |
Collapse
|
22
|
Argiro A, Rosenblum H, Griffin J, Batra J, Cappelli F, Burkhoff D, Maurer M, Olivotto I. Sex related differences in exercise performance in patients with hypertrophic cardiomyopathy: hemodynamic insights through non-invasive pressure volume analysis. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1558] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Women with HCM have worse cardiopulmonary exercise performance compared to men. We used non-invasive pressure-volume (PV) analysis to delineate sex related hemodynamic differences in HCM.
Methods
PV loops were constructed from echocardiograms using left ventricular (LV) volumes indexed to body surface area, Doppler estimates of LV end-diastolic pressure and blood pressure. The end-systolic PV relationship (ESPVR) and end-diastolic PV relationship (EDPVR) were derived from validated single-beat techniques. The area between the ESPVR and EDPVR (isovolumetric PV area), was indexed to an LV end-diastolic pressure of 30mmHg (PVAiso30), as the integrated metric of LV function. LV volume at an end-diastolic pressure of 30mmHg (V30) indexed ventricular capacity.
Results
202 patients were included, 56 women. Women were older (51 vs 44 yrs, p=0.012) and had reduced exercise capacity (5.6 vs 6.9 METs, p<0.001). Only 32 patients (16%) had a peak gradient >30mmHg at rest with no sex differences. Women had significantly lower indexed PVAiso30 (6577 vs 7767 mmHg·mL/m2, p<0.001) driven by reduced ventricular capacitance (V30 54 vs 62 ml/m2, p<0.001). In multivariable linear regression indexed V30 was an independent predictor of exercise capacity.
Conclusion
Impaired exercise capacity in women with HCM appears strongly related to abnormalities in passive diastolic properties, suggesting a unique pathophysiology compared to men, and a potential difference in viable therapeutic molecular targets
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- A Argiro
- Careggi University Hospital (AOUC), Cardiomyopathy Unit, Heart, Lung and Vessels Department, Florence, Italy
| | - H Rosenblum
- Columbia University Irving Medical Center-NYP Hospital, Division of Cardiology, Department of Medicine, New York, United States of America
| | - J Griffin
- Columbia University Irving Medical Center-NYP Hospital, Division of Cardiology, Department of Medicine, New York, United States of America
| | - J Batra
- Columbia University Irving Medical Center-NYP Hospital, Division of Cardiology, Department of Medicine, New York, United States of America
| | - F Cappelli
- Careggi University Hospital (AOUC), Cardiomyopathy Unit, Heart, Lung and Vessels Department, Florence, Italy
| | - D Burkhoff
- Cardiovascular Research Foundation, New York, United States of America
| | - M Maurer
- Columbia University Irving Medical Center-NYP Hospital, Division of Cardiology, Department of Medicine, New York, United States of America
| | - I Olivotto
- Careggi University Hospital (AOUC), Cardiomyopathy Unit, Heart, Lung and Vessels Department, Florence, Italy
| |
Collapse
|
23
|
Tsimbalyuk S, Smith KM, Edwards MR, Cross EM, Batra J, Soares da Costa TP, Aragão D, Basler CF, Forwood JK. Understanding viral host interactions that modulate nuclear transport and innate immunity. Acta Crystallogr A Found Adv 2021. [DOI: 10.1107/s0108767321095817] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
24
|
Golob S, Batra J, Godfrey S, Slomovich S, Fried J, Clerkin K, Griffin J, Takeda K, Naka Y, Topkara V, Habal M, Latif F, Restaino S, Farr M, Yuzefpolskaya M, Colombo P, Sayer G, Uriel N, Raikhelkar J. Clinical Characteristics and Outcomes of Cancer Survivors Undergoing Heart Transplantation. J Heart Lung Transplant 2021. [DOI: 10.1016/j.healun.2021.01.777] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
25
|
Jain A, Batra J, Lamperti M, Doyle DJ. Succinylcholine rescue for sugammadex-induced laryngospasm. Comment on Br J Anaesth 2020; 125: 423-5. Br J Anaesth 2020; 126:e58-e59. [PMID: 33250179 DOI: 10.1016/j.bja.2020.11.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2020] [Revised: 11/04/2020] [Accepted: 11/04/2020] [Indexed: 10/22/2022] Open
Affiliation(s)
- Amit Jain
- Anesthesiology Institute, Cleveland Clinic, Abu Dhabi, United Arab Emirates.
| | - Jaya Batra
- Anesthesiology Institute, Cleveland Clinic, Abu Dhabi, United Arab Emirates
| | - Massimo Lamperti
- Anesthesiology Institute, Cleveland Clinic, Abu Dhabi, United Arab Emirates
| | - D John Doyle
- Anesthesiology Institute, Cleveland Clinic, Case Western Reserve University, Cleveland, OH, USA
| |
Collapse
|
26
|
Bikdeli B, Madhavan MV, Gupta A, Jimenez D, Burton JR, Der Nigoghossian C, Chuich T, Nouri SN, Dreyfus I, Driggin E, Sethi S, Sehgal K, Chatterjee S, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Bertoletti L, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Tafur AJ, Francese DP, Batra J, Falanga A, Clerkin KJ, Uriel N, Kirtane A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Leon MB, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thromb Haemost 2020; 120:1004-1024. [PMID: 32473596 PMCID: PMC7516364 DOI: 10.1055/s-0040-1713152] [Citation(s) in RCA: 229] [Impact Index Per Article: 57.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct antithrombotic effects, other mechanisms of action, including anti-inflammatory or antiviral effects, have been postulated. Based on survey results from this group of authors, we suggest research priorities for specific agents and subgroups of patients with COVID-19. Further, we review other agents, including immunomodulators, that may have antithrombotic properties. It is our hope that the present document will encourage and stimulate future prospective studies and randomized trials to study the safety, efficacy, and optimal use of these agents for prevention or management of thrombosis in COVID-19.
Collapse
Affiliation(s)
- Behnood Bikdeli
- New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.,Center for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, Connecticut, United States.,Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, United States
| | - Mahesh V Madhavan
- New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.,Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, United States
| | - Aakriti Gupta
- New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.,Center for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, Connecticut, United States.,Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, United States
| | - David Jimenez
- Respiratory Department, Hospital Ramón y Cajal, Madrid, Spain.,Medicine Department, Universidad de Alcalá (IRYCIS), CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - John R Burton
- New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States
| | - Caroline Der Nigoghossian
- New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States
| | - Taylor Chuich
- New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States
| | - Shayan Nabavi Nouri
- New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States
| | - Isaac Dreyfus
- New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States
| | - Elissa Driggin
- New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States
| | - Sanjum Sethi
- New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States
| | - Kartik Sehgal
- Harvard Medical School, Boston, Massachusetts, United States.,Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
| | - Saurav Chatterjee
- North Shore and Long Island Jewish University Hospitals, Queens, New York, United States
| | - Walter Ageno
- Department of Medicine and Surgery, University of Insubria, Varese, Italy
| | - Mohammad Madjid
- McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas, United States
| | - Yutao Guo
- Department of Cardiology, Chinese PLA General Hospital, Beijing, China.,Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom
| | - Liang V Tang
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Yu Hu
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Laurent Bertoletti
- Department of "Médecine Vasculaire et Thérapeutique," CIC 1408, INNOVTE, CHU de St-Etienne and INSERM UMR1059, Université Jean-Monnet, Saint-Etienne, France
| | - Jay Giri
- Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States.,Penn Cardiovascular Outcomes, Quality, and Evaluative Research Center, Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania, United States.,Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, United States
| | - Mary Cushman
- Larner College of Medicine, University of Vermont, Burlington, Vermont, United States
| | - Isabelle Quéré
- Department of Vascular Medicine, University of Montpellier, Montpellier CHU, InnoVTE F-CRIN Network, Montpellier, France
| | - Evangelos P Dimakakos
- Oncology Unit GPP, Sotiria General Hospital, Athens School of Medicine, Athens, Greece
| | - C Michael Gibson
- Harvard Medical School, Boston, Massachusetts, United States.,Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
| | - Giuseppe Lippi
- Laboratory of Clinical Chemistry and Hematology, University Hospital of Verona, Verona, Italy
| | - Emmanuel J Favaloro
- Laboratory Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, NSW, Australia.,Sydney Centres for Thrombosis and Haemostasis, Westmead, NSW, Australia
| | - Jawed Fareed
- Loyola University Medical Center, Chicago, Illinois, United States
| | - Alfonso J Tafur
- Pritzker School of Medicine at the University of Chicago, Chicago, Illinois, United States.,Division of Vascular Medicine, Department of Medicine, NorthShore University HealthSystem, Skokie, Illinois, United States
| | - Dominic P Francese
- Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, United States
| | - Jaya Batra
- New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States
| | - Anna Falanga
- Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, University of Milan Bicocca, Bergamo, Italy
| | - Kevin J Clerkin
- New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States
| | - Nir Uriel
- New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States
| | - Ajay Kirtane
- New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.,Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, United States
| | | | | | - Alex C Spyropoulos
- The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, New York, United States
| | - Geoffrey D Barnes
- Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan, United States.,Frankel Cardiovascular Center, University of Michigan, Ann Arbor, Michigan, United States
| | - John W Eikelboom
- Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada
| | - Ido Weinberg
- Harvard Medical School, Boston, Massachusetts, United States.,Massachusetts General Hospital, Boston, Massachusetts, United States
| | - Sam Schulman
- Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.,McMaster University, Hamilton, Ontario, Canada.,Thrombosis & Atherosclerosis Research Institute, Hamilton, Ontario, Canada
| | - Marc Carrier
- The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| | - Gregory Piazza
- Harvard Medical School, Boston, Massachusetts, United States.,Brigham and Women's Hospital, Boston, Massachusetts, United States
| | - Joshua A Beckman
- Vanderbilt University School of Medicine, Nashville, Tennessee, United States
| | - Martin B Leon
- New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.,Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, United States
| | - Gregg W Stone
- Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, United States.,The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States
| | - Stephan Rosenkranz
- Department of Cardiology, Cologne Cardiovascular Research Center (CCRC), Heart Center at the University of Cologne, University of Cologne, Cologne, Germany
| | - Samuel Z Goldhaber
- Harvard Medical School, Boston, Massachusetts, United States.,Brigham and Women's Hospital, Boston, Massachusetts, United States
| | - Sahil A Parikh
- New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.,Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, United States
| | - Manuel Monreal
- Department of Internal Medicine, Hospital Universitari Germans Trials I Pujol, Universidad Católica de Murcia, Barcelona, Spain
| | - Harlan M Krumholz
- Center for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, Connecticut, United States.,Department of Health Policy and Administration, Yale School of Public Health, New Haven, Connecticut, United States.,Section of Cardiovascular Medicine, Department of Internal Medicie, Yale School of Medicine, New Haven, Connecticut, United States
| | | | - Jeffrey I Weitz
- McMaster University, Hamilton, Ontario, Canada.,Thrombosis & Atherosclerosis Research Institute, Hamilton, Ontario, Canada
| | - Gregory Y H Lip
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom.,Department of Clinical Medicine, Aalborg Thrombosis Research Unit, Aalborg University, Aalborg, Denmark
| | | |
Collapse
|
27
|
Batra J, Truby L, Garan R, Haythe J, Lin E, Axsom K, Yuzefpolskaya M, Colombo P, Sayer G, Takayama H, Takeda K, Naka Y, Farr M, Uriel N, Topkara V. C-reactive Protein Levels Predict Right Ventricular Failure and Mortality in Patients Undergoing Continuous-Flow Left Ventricular Assist Device Assist Device Implantation: An INTERMACS Analysis. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
28
|
Batra J, Marshall D, Jennings D, Truby L, DeFilippis E, Malick A, Butler C, Griffin J, Masoumi A, Clerkin K, Raikhelkar J, Fried J, Yuzefpolskaya M, Colombo P, Sayer G, Takayama H, Takeda K, Naka Y, Farr M, Topkara V, Uriel N. Elevated Serum C-reactive Protein (CRP) Level Predicts Increased Post-Implant Mortality in Patients Undergoing HeartMate 3 LVAD Implantation. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
29
|
Rose AM, Krishan A, Chakarova CF, Moya L, Chambers SK, Hollands M, Illingworth JC, Williams SMG, McCabe HE, Shah AZ, Palmer CNA, Chakravarti A, Berg JN, Batra J, Bhattacharya SS. MSR1 repeats modulate gene expression and affect risk of breast and prostate cancer. Ann Oncol 2019; 29:1292-1303. [PMID: 29509840 DOI: 10.1093/annonc/mdy082] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Background MSR1 repeats are a 36-38 bp minisatellite element that have recently been implicated in the regulation of gene expression, through copy number variation (CNV). Patients and methods Bioinformatic and experimental methods were used to assess the distribution of MSR1 across the genome, evaluate the regulatory potential of such elements and explore the role of MSR1 elements in cancer, particularly non-familial breast cancer and prostate cancer. Results MSR1s are predominately located at chromosome 19 and are functionally enriched in regulatory regions of the genome, particularly regions implicated in short-range regulatory activities (H3K27ac, H3K4me1 and H3K4me3). MSR1-regulated genes were found to have specific molecular roles, such as serine-protease activity (P = 4.80 × 10-7) and ion channel activity (P = 2.7 × 10-4). The kallikrein locus was found to contain a large number of MSR1 clusters, and at least six of these showed CNV. An MSR1 cluster was identified within KLK14, with 9 and 11 copies being normal variants. A significant association with the 9-copy allele and non-familial breast cancer was found in two independent populations (P = 0.004; P = 0.03). In the white British population, the minor allele conferred an increased risk of 1.21-3.51 times for all non-familial disease, or 1.7-5.3 times in early-onset disease. The 9-copy allele was also found to be associated with increased risk of prostate cancer in an independent population (odds ratio = 1.27-1.56; P =0.009). Conclusions MSR1 repeats act as molecular switches that modulate gene expression. It is likely that CNV of MSR1 will affect risk of development of various forms of cancer, including that of breast and prostate. The MSR1 cluster at KLK14 represents the strongest risk factor identified to date in non-familial breast cancer and a significant risk factor for prostate cancer. Analysis of MSR1 genotype will allow development of precise stratification of disease risk and provide a novel target for therapeutic agents.
Collapse
Affiliation(s)
- A M Rose
- Department of Genetics, UCL Institute of Ophthalmology, University College London, London, UK.
| | - A Krishan
- Cell Therapy and Regenerative Medicine, CABIMER, Seville, Spain
| | - C F Chakarova
- Department of Genetics, UCL Institute of Ophthalmology, University College London, London, UK
| | - L Moya
- Australian Prostate Cancer Research Centre - Queensland, Translational Research Institute, Brisbane; Cancer Program, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane
| | - S K Chambers
- Menzies Health Institute Queensland, Griffith University, Southport; Cancer Research Centre, Cancer Council Queensland, Brisbane, Australia
| | - M Hollands
- UCL Medical School, University College London, London
| | | | | | - H E McCabe
- Clinical Genetics, Ninewells Hospital & Medical School, University of Dundee, Dundee
| | - A Z Shah
- Department of Genetics, UCL Institute of Ophthalmology, University College London, London, UK
| | - C N A Palmer
- Centre for Pharmacogenetics and Pharmacogenomics, Ninewells Hospital and School of Medicine, University of Dundee, Dundee, UK
| | - A Chakravarti
- Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, USA
| | - J N Berg
- Clinical Genetics, Ninewells Hospital & Medical School, University of Dundee, Dundee
| | - J Batra
- Australian Prostate Cancer Research Centre - Queensland, Translational Research Institute, Brisbane; Cancer Program, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane
| | - S S Bhattacharya
- Department of Genetics, UCL Institute of Ophthalmology, University College London, London, UK; Cell Therapy and Regenerative Medicine, CABIMER, Seville, Spain
| |
Collapse
|
30
|
Batra J, Jennings D, Garan A, Truby L, Latif F, Restaino S, Haythe J, Yuzefpolskaya M, Takeda K, Takayama H, Naka Y, Colombo P, Farr M, Topkara V. Outcomes after Early Initiation of mTOR-Inhibitors in Adult Cardiac Transplant Recipients. J Heart Lung Transplant 2019. [DOI: 10.1016/j.healun.2019.01.695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
31
|
Allaway RJ, Wood MD, Downey SL, Bouley SJ, Traphagen NA, Wells JD, Batra J, Melancon SN, Ringelberg C, Seibel W, Ratner N, Sanchez Y. Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells. Oncotarget 2018; 9:15860-15875. [PMID: 29662612 PMCID: PMC5882303 DOI: 10.18632/oncotarget.19335] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2016] [Accepted: 07/09/2017] [Indexed: 11/26/2022] Open
Abstract
Neurofibromatosis type 1 is a disease caused by mutation of neurofibromin 1 (NF1), loss of which results in hyperactive Ras signaling and a concomitant increase in cell proliferation and survival. Patients with neurofibromatosis type 1 frequently develop tumors such as plexiform neurofibromas and malignant peripheral nerve sheath tumors. Mutation of NF1 or loss of the NF1 protein is also observed in glioblastoma, lung adenocarcinoma, and ovarian cancer among other sporadic cancers. A therapy that selectively targets NF1 deficient tumors would substantially advance our ability to treat these malignancies. To address the need for these therapeutics, we developed and conducted a synthetic lethality screen to discover molecules that target yeast lacking the homolog of NF1, IRA2. One of the lead candidates that was observed to be synthetic lethal with ira2Δ yeast is Y100. Here, we describe the mechanisms by which Y100 targets ira2Δ yeast and NF1-deficient tumor cells. Y100 treatment disrupted proteostasis, metabolic homeostasis, and induced the formation of mitochondrial superoxide in NF1-deficient cancer cells. Previous studies also indicate that NF1/Ras-dysregulated tumors may be sensitive to modulators of oxidative and ER stress. We hypothesize that the use of Y100 and molecules with related mechanisms of action represent a feasible therapeutic strategy for targeting NF1 deficient cells.
Collapse
Affiliation(s)
- Robert J. Allaway
- Department of Molecular and Systems Biology, Geisel School of Medicine, Dartmouth College, Hanover, NH 03755, USA
| | - Matthew D. Wood
- Department of Pharmacology and Toxicology, Geisel School of Medicine, Dartmouth College, Hanover, NH 03755, USA
- Current address: Department of Pathology, University of California San Francisco, San Francisco, CA 94143, USA
| | - Sondra L. Downey
- Department of Pharmacology and Toxicology, Geisel School of Medicine, Dartmouth College, Hanover, NH 03755, USA
| | - Stephanie J. Bouley
- Department of Molecular and Systems Biology, Geisel School of Medicine, Dartmouth College, Hanover, NH 03755, USA
| | - Nicole A. Traphagen
- Department of Molecular and Systems Biology, Geisel School of Medicine, Dartmouth College, Hanover, NH 03755, USA
| | - Jason D. Wells
- Department of Epidemiology, Geisel School of Medicine, Dartmouth College, Hanover, NH 03755, USA
| | - Jaya Batra
- Department of Pharmacology and Toxicology, Geisel School of Medicine, Dartmouth College, Hanover, NH 03755, USA
- Current address: Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Sir Norman Melancon
- Department of Pharmacology and Toxicology, Geisel School of Medicine, Dartmouth College, Hanover, NH 03755, USA
- Current address: Vanderbilt School of Medicine, Nashville, TN 37232, USA
| | - Carol Ringelberg
- Department of Molecular and Systems Biology, Geisel School of Medicine, Dartmouth College, Hanover, NH 03755, USA
- Bioinformatics Shared Resource, Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA
| | - William Seibel
- Division of Oncology, Cincinnati Children’s Hospital Medical Center, Cancer and Blood Diseases Institute, Cincinnati, OH 45229, USA
| | - Nancy Ratner
- Division of Experimental Hematology and Cancer Biology, Cincinnati Children’s Hospital Medical Center, Cancer and Blood Diseases Institute, Cincinnati, OH 45229, USA
| | - Yolanda Sanchez
- Department of Molecular and Systems Biology, Geisel School of Medicine, Dartmouth College, Hanover, NH 03755, USA
- Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA
| |
Collapse
|
32
|
Batra J, Toyoda N, Goldstone AB, Itagaki S, Egorova NN, Chikwe J. Extracorporeal Membrane Oxygenation in New York State: Trends, Outcomes, and Implications for Patient Selection. Circ Heart Fail 2017; 9:CIRCHEARTFAILURE.116.003179. [PMID: 27940495 DOI: 10.1161/circheartfailure.116.003179] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/24/2016] [Accepted: 11/09/2016] [Indexed: 11/16/2022]
Abstract
BACKGROUND Utilization of extracorporeal membrane oxygenation (ECMO) is expanding despite limited outcome data defining appropriate use. METHODS AND RESULTS To quantify determinants of early and 1-year survival after ECMO in adult patients, we conducted a retrospective cohort analysis of 1286 patients aged ≥18 years who underwent ECMO in New York State from 2003 to 2014. Median follow-up time was 4.9 months (range, 0-12 months). ECMO utilization increased from 13 patients in 8 hospitals in 2003 to 330 patients in 30 hospitals in 2014. Compared with patients undergoing ECMO before 2009, later patients were older (54.4 versus 52.3 years; P=0.013) and more likely to have major comorbidity including chronic kidney disease (25.2% versus 13.2%; P=0.02) and liver disease (20.0% versus 10.7%; P=0.001). In the overall cohort, 30-day mortality was 52.2% (95% confidence interval, 49.5-54.9). Mortality at 30 days was 65.2% for patients aged ≥75 years (n=73/112) and 74.6% in patients who required cardiopulmonary resuscitation (n=91/122). Survival at 1 year was 38.4% (95% confidence interval, 35.7-41.0). The 30-day mortality and 1-year survival improved across the study period. In multivariable analysis, earlier year of ECMO, lower hospital volume, indication for ECMO after a cardiac procedure, cardiopulmonary resuscitation before ECMO placement, and age >65 years were independent predictors of worse survival. CONCLUSIONS Outcomes of ECMO have improved despite increasing comorbidity. Extreme mortality after ECMO in elderly patients and patients requiring cardiopulmonary resuscitation indicates that less invasive therapeutic or palliative modalities may be more appropriate in this end-of-life setting.
Collapse
Affiliation(s)
- Jaya Batra
- From the Department of Cardiovascular Surgery (J.B., N.T., S.I., J.C.) and Department of Population Health Science and Policy (N.N.E.), Icahn School of Medicine at Mount Sinai, New York, NY; and Department of Cardiothoracic Surgery, Stanford University School of Medicine, CA (A.B.G.)
| | - Nana Toyoda
- From the Department of Cardiovascular Surgery (J.B., N.T., S.I., J.C.) and Department of Population Health Science and Policy (N.N.E.), Icahn School of Medicine at Mount Sinai, New York, NY; and Department of Cardiothoracic Surgery, Stanford University School of Medicine, CA (A.B.G.)
| | - Andrew B Goldstone
- From the Department of Cardiovascular Surgery (J.B., N.T., S.I., J.C.) and Department of Population Health Science and Policy (N.N.E.), Icahn School of Medicine at Mount Sinai, New York, NY; and Department of Cardiothoracic Surgery, Stanford University School of Medicine, CA (A.B.G.)
| | - Shinobu Itagaki
- From the Department of Cardiovascular Surgery (J.B., N.T., S.I., J.C.) and Department of Population Health Science and Policy (N.N.E.), Icahn School of Medicine at Mount Sinai, New York, NY; and Department of Cardiothoracic Surgery, Stanford University School of Medicine, CA (A.B.G.)
| | - Natalia N Egorova
- From the Department of Cardiovascular Surgery (J.B., N.T., S.I., J.C.) and Department of Population Health Science and Policy (N.N.E.), Icahn School of Medicine at Mount Sinai, New York, NY; and Department of Cardiothoracic Surgery, Stanford University School of Medicine, CA (A.B.G.)
| | - Joanna Chikwe
- From the Department of Cardiovascular Surgery (J.B., N.T., S.I., J.C.) and Department of Population Health Science and Policy (N.N.E.), Icahn School of Medicine at Mount Sinai, New York, NY; and Department of Cardiothoracic Surgery, Stanford University School of Medicine, CA (A.B.G.).
| |
Collapse
|
33
|
Tagawa S, Scherr D, Batra J, Jhanwar Y, Robinson B, Nanus D, Beltran H, Molina A, Christos P, Bander N. Anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 immunotherapy for prostate cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw372.55] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
34
|
NDong C, Tate JA, Kett WC, Batra J, Demidenko E, Lewis LD, Hoopes PJ, Gerngross TU, Griswold KE. Tumor cell targeting by iron oxide nanoparticles is dominated by different factors in vitro versus in vivo. PLoS One 2015; 10:e0115636. [PMID: 25695795 PMCID: PMC4335054 DOI: 10.1371/journal.pone.0115636] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2014] [Accepted: 11/25/2014] [Indexed: 11/29/2022] Open
Abstract
Realizing the full potential of iron oxide nanoparticles (IONP) for cancer diagnosis and therapy requires selective tumor cell accumulation. Here, we report a systematic analysis of two key determinants for IONP homing to human breast cancers: (i) particle size and (ii) active vs passive targeting. In vitro, molecular targeting to the HER2 receptor was the dominant factor driving cancer cell association. In contrast, size was found to be the key determinant of tumor accumulation in vivo, where molecular targeting increased tumor tissue concentrations for 30 nm but not 100 nm IONP. Similar to the in vitro results, PEGylation did not influence in vivo IONP biodistribution. Thus, the results reported here indicate that the in vitro advantages of molecular targeting may not consistently extend to pre-clinical in vivo settings. These observations may have important implications for the design and clinical translation of advanced, multifunctional, IONP platforms.
Collapse
Affiliation(s)
- Christian NDong
- Thayer School of Engineering, Dartmouth, Hanover, NH, United States of America
| | - Jennifer A. Tate
- Thayer School of Engineering, Dartmouth, Hanover, NH, United States of America
| | - Warren C. Kett
- Thayer School of Engineering, Dartmouth, Hanover, NH, United States of America
| | - Jaya Batra
- Thayer School of Engineering, Dartmouth, Hanover, NH, United States of America
| | - Eugene Demidenko
- Department of Biostatistics and Medicine, The Geisel School of Medicine at Dartmouth, Lebanon, NH, United States of America
| | - Lionel D. Lewis
- Department of Biostatistics and Medicine, The Geisel School of Medicine at Dartmouth, Lebanon, NH, United States of America
| | - P. Jack Hoopes
- Department of Biostatistics and Medicine, The Geisel School of Medicine at Dartmouth, Lebanon, NH, United States of America
| | - Tillman U. Gerngross
- Thayer School of Engineering, Dartmouth, Hanover, NH, United States of America
- Department of Biological Sciences, Dartmouth, Hanover, NH, United States of America
- Department of Chemistry, Dartmouth, Hanover, NH, United States of America
| | - Karl E. Griswold
- Thayer School of Engineering, Dartmouth, Hanover, NH, United States of America
- Program in Molecular and Cellular Biology, Dartmouth, Hanover, NH, United States of America
- Department of Biological Sciences, Dartmouth, Hanover, NH, United States of America
- * E-mail:
| |
Collapse
|
35
|
Batra J, Attresh G, Garg B. Response to "Transpalatal screw traction: a simple technique for the management of sagittal fractures of the maxilla and palate". Int J Oral Maxillofac Surg 2015; 44:670-1. [PMID: 25684351 DOI: 10.1016/j.ijom.2015.01.016] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2014] [Accepted: 01/21/2015] [Indexed: 11/18/2022]
Affiliation(s)
- J Batra
- Post Graduate Institute of Dental Sciences, Pt. B.D Sharma UHS, Rohtak, Haryana India.
| | - G Attresh
- Post Graduate Institute of Dental Sciences, Pt. B.D Sharma UHS, Rohtak, Haryana India
| | - B Garg
- Post Graduate Institute of Dental Sciences, Pt. B.D Sharma UHS, Rohtak, Haryana India
| |
Collapse
|
36
|
Kote-Jarai Z, Amin Al Olama A, Leongamornlert D, Tymrakiewicz M, Saunders E, Guy M, Giles GG, Severi G, Southey M, Hopper JL, Sit KC, Harris JM, Batra J, Spurdle AB, Clements JA, Hamdy F, Neal D, Donovan J, Muir K, Pharoah PDP, Chanock SJ, Brown N, Benlloch S, Castro E, Mahmud N, O'Brien L, Hall A, Sawyer E, Wilkinson R, Easton DF, Eeles RA. Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. Hum Genet 2011; 129:687-94. [PMID: 21465221 PMCID: PMC3092928 DOI: 10.1007/s00439-011-0981-1] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2011] [Accepted: 03/14/2011] [Indexed: 11/29/2022]
Abstract
Genome-wide association studies (GWAS) have identified more than 30 prostate cancer (PrCa) susceptibility loci. One of these (rs2735839) is located close to a plausible candidate susceptibility gene, KLK3, which encodes prostate-specific antigen (PSA). PSA is widely used as a biomarker for PrCa detection and disease monitoring. To refine the association between PrCa and variants in this region, we used genotyping data from a two-stage GWAS using samples from the UK and Australia, and the Cancer Genetic Markers of Susceptibility (CGEMS) study. Genotypes were imputed for 197 and 312 single nucleotide polymorphisms (SNPs) from HapMap2 and the 1000 Genome Project, respectively. The most significant association with PrCa was with a previously unidentified SNP, rs17632542 (combined P = 3.9 × 10−22). This association was confirmed by direct genotyping in three stages of the UK/Australian GWAS, involving 10,405 cases and 10,681 controls (combined P = 1.9 × 10−34). rs17632542 is also shown to be associated with PSA levels and it is a non-synonymous coding SNP (Ile179Thr) in KLK3. Using molecular dynamic simulation, we showed evidence that this variant has the potential to introduce alterations in the protein or affect RNA splicing. We propose that rs17632542 may directly influence PrCa risk.
Collapse
Affiliation(s)
- Z Kote-Jarai
- The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Batra J, Pratap Singh T, Mabalirajan U, Sinha A, Prasad R, Ghosh B. Association of inducible nitric oxide synthase with asthma severity, total serum immunoglobulin E and blood eosinophil levels. Thorax 2006. [DOI: 10.1136/thx.2005.057935] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
38
|
Chatterjee R, Batra J, Kumar A, Mabalirajan U, Nahid S, Niphadkar PV, Ghosh B. Interleukin-10 promoter polymorphisms and atopic asthma in North Indians. Clin Exp Allergy 2006; 35:914-9. [PMID: 16008678 DOI: 10.1111/j.1365-2222.2005.02273.x] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND IL-10 is an anti-inflammatory cytokine primarily produced by monocytes and macrophages and plays a key role in asthma. IL10 gene, present in chromosome 1q31-q32, is regulated primarily by transcription and its expression is found to be lower in asthmatics. Earlier studies in diverse populations have identified several promoter polymorphisms. However, no study has been carried out in a genetically untapped large population from the Indian Subcontinent. OBJECTIVE To investigate the association of the IL10 promoter polymorphisms and asthma in the North Indian population. METHODS The association study was conducted in a case-control as well as in a family-based design. Polymorphism at -1082 A/G, -819 C/T and -592 C/A nucleotides were genotyped in ethnically matched unrelated patients (N=272), unrelated controls (N=307) and nuclear families (N=164). RESULTS A suggestive evidence of association was obtained for -1082 A/G polymorphism at the level of alleles and genotypes with asthma in the case-control study (P=0.03). A three-locus haplotype (ATA) was found to be more in asthmatics than in control individuals (P=0.0085). On the other hand, a novel haplotype ATC was found to be more in controls than in asthmatics (P=0.012). These results were further tested in a family-based study. A deviation of transmission was observed for the -1082 A/G polymorphism (P=0.003). The ATA haplotype showed a preferential transmission in asthmatics (P=0.03), while the GCC and a novel ATC haplotype showed preferential non-transmission in asthmatic individuals (P=0.03 and 0.001, respectively). CONCLUSIONS Using both case-control and family studies, we provide suggestive evidence that the ATA haplotype is positively, whereas GCC and a novel ATC haplotypes of IL10 gene are negatively associated with asthma in Indian population. Our results are interesting enough as to intensify further research to elucidate the functional significance of these single-nucleotide polymorphisms and haplotypes in asthma pathogenesis.
Collapse
Affiliation(s)
- R Chatterjee
- Institute of Genomics and Integrative Biology, Mall Road, Delhi, India
| | | | | | | | | | | | | |
Collapse
|
39
|
Batra J, Sharma M, Chatterjee R, Sharma S, Mabalirajan U, Ghosh B. CCR5 Delta32 deletion and atopic asthma in India. Thorax 2005; 60:85. [PMID: 15618591 PMCID: PMC1747173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/01/2023]
|
40
|
Bhatia A, Bhatia V, Batra J, Mahajan DS, Bal BS, Batra KS. Congenital valvular aortic and pulmonary stenosis. J Assoc Physicians India 1998; 46:566-7. [PMID: 11273263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Affiliation(s)
- A Bhatia
- Guru Nanak Dev Hospital, Medical College, Amritsar, 143001, Punjab-India
| | | | | | | | | | | |
Collapse
|
41
|
Fischer PH, Bird RE, Kasprzyk PG, King CR, Turner NA, Pastan I, Kihara A, Batra J. In vitro and in vivo activity of a recombinant toxin, OLX-209, which targets the erbB-2 oncoprotein. Adv Enzyme Regul 1994; 34:119-28. [PMID: 7942269 DOI: 10.1016/0065-2571(94)90012-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
OLX-209 has readily measurable activity, is safe in experimental animals, and is efficacious in model systems. These results support the concept of OLX-209 and provide groundwork for further development of this oncoprotein targeted agent.
Collapse
|